- Home
- MTNB vs SCNI Comparison
MTNB vs SCNI Comparison
Compare MTNB & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTNB
- SCNI
- Stock Information
- Founded
- MTNB 2013
- SCNI 2003
- Country
- MTNB United States
- SCNI Israel
- Employees
- MTNB N/A
- SCNI N/A
- Industry
- MTNB Biotechnology: Pharmaceutical Preparations
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MTNB Health Care
- SCNI Health Care
- Exchange
- MTNB Nasdaq
- SCNI Nasdaq
- Market Cap
- MTNB 3.6M
- SCNI 3.2M
- IPO Year
- MTNB N/A
- SCNI N/A
- Fundamental
- Price
- MTNB $0.94
- SCNI $2.27
- Analyst Decision
- MTNB Hold
- SCNI
- Analyst Count
- MTNB 1
- SCNI 0
- Target Price
- MTNB N/A
- SCNI N/A
- AVG Volume (30 Days)
- MTNB 376.6K
- SCNI 1.1M
- Earning Date
- MTNB 08-13-2025
- SCNI 08-14-2025
- Dividend Yield
- MTNB N/A
- SCNI N/A
- EPS Growth
- MTNB N/A
- SCNI N/A
- EPS
- MTNB N/A
- SCNI N/A
- Revenue
- MTNB N/A
- SCNI $658,000.00
- Revenue This Year
- MTNB N/A
- SCNI N/A
- Revenue Next Year
- MTNB N/A
- SCNI N/A
- P/E Ratio
- MTNB N/A
- SCNI N/A
- Revenue Growth
- MTNB N/A
- SCNI N/A
- 52 Week Low
- MTNB $0.47
- SCNI $1.90
- 52 Week High
- MTNB $9.60
- SCNI $8.92
- Technical
- Relative Strength Index (RSI)
- MTNB 56.79
- SCNI 44.70
- Support Level
- MTNB $0.88
- SCNI $2.14
- Resistance Level
- MTNB $1.04
- SCNI $2.85
- Average True Range (ATR)
- MTNB 0.09
- SCNI 0.20
- MACD
- MTNB -0.01
- SCNI 0.01
- Stochastic Oscillator
- MTNB 30.17
- SCNI 20.55
About MTNB Matinas Biopharma Holdings Inc.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.